Shaomeng Wang
Chinese-American Pharmacological chemist
Shaomeng Wang's AcademicInfluence.com Rankings

Download Badge
Medical
Shaomeng Wang's Degrees
- Bachelors Chemistry Peking University
- PhD Pharmacology University of California, San Francisco
Why Is Shaomeng Wang Influential?
(Suggest an Edit or Addition)According to Wikipedia, Shaomeng Wang is a Chinese-American chemist currently the Warner-Lambert/Parke-Davis Professor in Medicine at University of Michigan and a former Co-Editor-in-Chief at American Chemical Society's Journal of Medicinal Chemistry. A cited expert in his field, his interests are synthesis and design of moleculars, neurological diseases and computational and informatics. He was Elected as Fellow at the National Academy of Inventors in 2014. Dr. Wang was named to the AAAS Fellows Section on Pharmaceutical Sciences in 2019, and is the recipient of the Division of Medicinal Chemistry Award 2020 American Chemical Society.
Shaomeng Wang's Published Works
Published Works
- Small-Molecule Inhibitors of the MDM2–p53 Protein–Protein Interaction (MDM2 Inhibitors) in Clinical Trials for Cancer Treatment (2014) (371)
- The Ecstasy and Agony of Assay Interference Compounds. (2017) (83)
- Structure-Based Design of Conformationally Constrained, Cell-Permeable STAT3 Inhibitors. (2010) (83)
- Simple Structural Modifications Converting a Bona Fide MDM2 PROTAC Degrader into a Molecular Glue Molecule: A Cautionary Tale in the Design of PROTAC Degraders. (2019) (75)
- The making of I-BET762, a BET bromodomain inhibitor now in clinical development. (2013) (74)
- Structure-based design of high-affinity macrocyclic peptidomimetics to block the menin-mixed lineage leukemia 1 (MLL1) protein-protein interaction. (2013) (70)
- Discovery of SHP2-D26 as a First, Potent, and Effective PROTAC Degrader of SHP2 Protein. (2020) (63)
- Analysis of the binding of mixed lineage leukemia 1 (MLL1) and histone 3 peptides to WD repeat domain 5 (WDR5) for the design of inhibitors of the MLL1-WDR5 interaction. (2010) (59)
- The Ecstasy and Agony of Assay Interference Compounds (2017) (53)
- LDK378: a promising anaplastic lymphoma kinase (ALK) inhibitor. (2013) (45)
- The Ecstasy and Agony of Assay Interference Compounds. (2017) (44)
- Artificial Intelligence in Drug Discovery: Into the Great Wide Open. (2020) (38)
- AM-8553: a novel MDM2 inhibitor with a promising outlook for potential clinical development. (2012) (33)
- The Ecstasy and Agony of Assay Interference Compounds. (2017) (32)
- Potent 5-Cyano-6-phenyl-pyrimidin-Based Derivatives Targeting DCN1-UBE2M Interaction. (2019) (24)
- Inducing Protein Degradation as a Therapeutic Strategy. (2016) (23)
- Epigenetics: Novel Therapeutics Targeting Epigenetics. (2015) (16)
- Absolute Quantitative 1H NMR Spectroscopy for Compound Purity Determination (2014) (13)
- The Ecstasy and Agony of Assay Interference Compounds. (2017) (12)
- Epigenetics: novel therapeutics targeting epigenetics. (2015) (12)
- Digital chemistry in the Journal of Medicinal Chemistry. (2014) (8)
- The Ecstasy and Agony of Assay Interference Compounds. (2017) (7)
- Update to Our Reader, Reviewer, and Author Communities-April 2020. (2020) (6)
- Confronting Racism in Chemistry Journals. (2020) (6)
- Women in Medicinal Chemistry Special Issue Call for Papers. (2019) (6)
- The Ecstasy and Agony of Assay Interference Compounds. (2017) (6)
- Transition in leadership: opportunities and challenges. (2012) (6)
- New Horizons in Drug Discovery - Understanding and Advancing Kinase Inhibitors. (2020) (4)
- The Ecstasy and Agony of Assay Interference Compounds. (2017) (4)
- Confronting Racism in Chemistry Journals. (2020) (3)
- Confronting Racism in Chemistry Journals. (2020) (3)
- The 2020 Nobel Prize in Physiology or Medicine. (2020) (3)
- Women in Medicinal Chemistry: Ad Maiora! (2020) (3)
- Confronting Racism in Chemistry Journals. (2020) (3)
- Confronting Racism in Chemistry Journals. (2020) (2)
- The Future Is Now: Artificial Intelligence in Drug Discovery. (2019) (2)
- Update to Our Reader, Reviewer, and Author Communities—April 2020 (2020) (2)
- Confronting Racism in Chemistry Journals. (2020) (2)
- Confronting Racism in Chemistry Journals. (2020) (1)
- Update to Our Reader, Reviewer, and Author Communities-April 2020. (2020) (1)
- Confronting Racism in Chemistry Journals. (2020) (1)
- Introduction: Drug Metabolism and Toxicology Special Issue. (2020) (1)
- Confronting Racism in Chemistry Journals. (2020) (1)
- Epigenetics 2.0: Special Issue on Epigenetics-Call for Papers. (2020) (1)
- Drug Annotations for a New Decade. (2020) (1)
- Update to Our Reader, Reviewer, and Author Communities-April 2020. (2020) (1)
- Advances toward COVID-19 Therapies Special Issue Call for Papers. (2020) (1)
- Update to Our Reader, Reviewer, and Author Communities-April 2020. (2020) (1)
- Confronting Racism in Chemistry Journals. (2020) (0)
- Confronting Racism in Chemistry Journals. (2020) (0)
- Update to Our Reader, Reviewer, and Author Communities-April 2020. (2020) (0)
- Confronting Racism in Chemistry Journals. (2020) (0)
- Confronting Racism in Chemistry Journals. (2020) (0)
- Confronting Racism in Chemistry Journals. (2020) (0)
- Update to Our Reader, Reviewer, and Author Communities-April 2020. (2020) (0)
- Update to Our Reader, Reviewer, and Author Communities-April 2020. (2020) (0)
- Confronting Racism in Chemistry Journals (2020) (0)
- Update to Our Reader, Reviewer, and Author Communities-April 2020. (2020) (0)
- Update to Our Reader, Reviewer, and Author Communities-April 2020. (2020) (0)
- Drug Metabolism and Toxicology Special Issue Call for Papers. (2019) (0)
- Allosteric Modulators of Drug Targets Special Issue. (2018) (0)
- Confronting Racism in Chemistry Journals. (2020) (0)
- Confronting Racism in Chemistry Journals. (2020) (0)
- Update to Our Reader, Reviewer, and Author Communities-April 2020. (2020) (0)
- Confronting Racism in Chemistry Journals. (2020) (0)
- Alzheimer's disease special thematic issue: call for papers. (2012) (0)
- Update to Our Reader, Reviewer, and Author Communities-April 2020. (2020) (0)
- Confronting Racism in Chemistry Journals. (2020) (0)
- A Message from the Editors-in-Chief. (2019) (0)
- Confronting Racism in Chemistry Journals (2020) (0)
- Confronting Racism in Chemistry Journals. (2020) (0)
- Confronting Racism in Chemistry Journals. (2020) (0)
- Drug Metabolism and Toxicology Special Issue Call for Papers. (2019) (0)
- Confronting Racism in Chemistry Journals. (2020) (0)
- Update to Our Reader, Reviewer, and Author Communities-April 2020. (2020) (0)
- Update to Our Reader, Reviewer, and Author Communities-April 2020. (2020) (0)
- Update to Our Reader, Reviewer, and Author Communities-April 2020. (2020) (0)
- Update to Our Reader, Reviewer, and Author Communities-April 2020. (2020) (0)
- Update to Our Reader, Reviewer, and Author Communities-April 2020. (2020) (0)
- Confronting Racism in Chemistry Journals. (2020) (0)
- Update to Our Reader, Reviewer, and Author Communities-April 2020. (2020) (0)
- Update to Our Reader, Reviewer, and Author Communities-April 2020. (2020) (0)
- Update to Our Reader, Reviewer, and Author Communities-April 2020. (2020) (0)
- Confronting Racism in Chemistry Journals. (2020) (0)
- Correction to Potent 5-Cyano-6-phenyl-pyrimidin-Based Derivatives Targeting DCN1-UBE2M Interaction. (2020) (0)
- Update to Our Reader, Reviewer, and Author Communities-April 2020. (2020) (0)
- Update to Our Reader, Reviewer, and Author Communities-April 2020. (2020) (0)
- Current Medicinal Chemistry Research in India: Progress and Opportunities. (2017) (0)
- Update to Our Reader, Reviewer, and Author Communities-April 2020. (2020) (0)
- Update to Our Reader, Reviewer, and Author Communities—April 2020 (2020) (0)
- Update to Our Reader, Reviewer, and Author Communities-April 2020. (2020) (0)
- Confronting Racism in Chemistry Journals (2020) (0)
- Update to Our Reader, Reviewer, and Author Communities-April 2020. (2020) (0)
- Confronting Racism in Chemistry Journals. (2020) (0)
- Update to Our Reader, Reviewer, and Author Communities-April 2020. (2020) (0)
- Confronting Racism in Chemistry Journals. (2020) (0)
- Confronting Racism in Chemistry Journals. (2020) (0)
- Confronting Racism in Chemistry Journals. (2020) (0)
- Update to Our Reader, Reviewer, and Author Communities - April 2020 (2020) (0)
- Confronting Racism in Chemistry Journals. (2020) (0)
- Confronting Racism in Chemistry Journals. (2020) (0)
- Update to Our Reader, Reviewer, and Author Communities-April 2020. (2020) (0)
- Update to Our Reader, Reviewer, and Author Communities-April 2020. (2020) (0)
- Update to Our Reader, Reviewer, and Author Communities—April 2020 (2020) (0)
- Update to Our Reader, Reviewer, and Author Communities-April 2020. (2020) (0)
- Confronting Racism in Chemistry Journals. (2020) (0)
- Confronting Racism in Chemistry Journals. (2020) (0)
- Update to Our Reader, Reviewer, and Author Communities-April 2020. (2020) (0)
- Confronting Racism in Chemistry Journals. (2020) (0)
- Confronting Racism in Chemistry Journals. (2020) (0)
- Editorial Confronting Racism in Chemistry Journals (2020) (0)
- Confronting Racism in Chemistry Journals. (2020) (0)
- Hepatitis C virus (HCV) therapies special thematic issue: call for papers. (2013) (0)
- Update to Our Reader, Reviewer, and Author Communities-April 2020. (2020) (0)
- Update to Our Reader, Reviewer, and Author Communities-April 2020. (2020) (0)
- Confronting Racism in Chemistry Journals. (2020) (0)
- Update to Our Reader, Reviewer, and Author Communities-April 2020. (2020) (0)
- Update to Our Reader, Reviewer, and Author Communities-April 2020. (2020) (0)
- Update to Our Reader, Reviewer, and Author Communities-April 2020. (2020) (0)
- Update to Our Reader, Reviewer, and Author Communities-April 2020. (2020) (0)
- Confronting Racism in Chemistry Journals. (2020) (0)
- Confronting Racism in Chemistry Journals. (2020) (0)
This paper list is powered by the following services:
Other Resources About Shaomeng Wang
What Schools Are Affiliated With Shaomeng Wang?
Shaomeng Wang is affiliated with the following schools: